LY4064809 + esomeprazole

LY4064809 + esomeprazole is an oral combination comprising LY4064809, a novel investigational compound whose mechanism of action and targeted indication have not been publicly detailed, and esomeprazole, a well-established proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase (proton pump) in parietal cells. This combination is being studied to assess the impact of gastric acid suppression (by esomeprazole) on the pharmacokinetics and safety of LY4064809 in healthy adults; the rationale is that PPIs can influence the absorption of co-administered drugs whose bioavailability may be pH dependent. As of mid-2025, available clinical data focus on characterizing drug-drug interaction, food effects, and safety in healthy volunteers[1][2][3][4][7].